HOME >> BIOLOGY >> NEWS
Studies show success of Mectizan partnerships

The development of the drug Mectizan (ivermectin) and its distribution worldwide have radically altered the consequences of onchocerciasis, or river blindness, which once blinded millions in Africa, and Latin America. Researchers at the Johns Hopkins Bloomberg School of Public Health conducted four new studies evaluating the Mectizan Donation Program, which was established by Merck and Co. Inc., the makers of Mectizan. They concluded that the now 17-year old Mectizan Donation Program is a successful and cost effective program for preventing the debilitating effects of river blindness. The researchers also believe that the public-private partnership forged by Merck through the Mectizan Donation Program should serve as a model for other companies and aid organizations seeking to prevent and treat other illnesses worldwide, such as AIDS and malaria. The studies are published in the current issue the journal Tropical Medicine and International Health.

On May 14, 2004, the School of Public Health and Merck and Co. Inc., will mark the successful work of the Mectizan Distribution Program with a symposium, "Controlling River Blindness: Achievements of a Public-Private Partnership." The event will be held from 12:15-1:30 p.m. at the School of Public Health in Baltimore, Md. and will feature discussions of the latest study findings from researchers from the School of Public Health and representatives from Merck and the Mectizan Donation Program.

"The Mectizan Donation Program is really one of the great public health success stories. It is the benchmark for all other disease prevention efforts in the developing world," said Gilbert Burnham, MD, one of the study authors and an associate professor in the School's Department of International Health.

Ivermectin, the compound from which Mectizan is derived, was originally found to be effective against parasites in farm animals. Realizing its potential as a human medicine, Merck and WHO conducted seven years of
'"/>

Contact: Tim Parsons
paffairs@jhsph.edu
410-955-6878
Johns Hopkins University Bloomberg School of Public Health
10-May-2004


Page: 1 2

Related biology news :

1. Monkey business: Studies show tiny callimicos have unusual characteristics
2. Studies offer new insight into HIV vaccine development
3. Studies suggest brain injury results from developmental exposure to alcohol, anesthesia, and lead
4. Studies show preventive value of food supplements
5. Studies probe rapid evolution of Chinese tallow trees
6. Studies of rare blood syndrome yield novel route to cancer
7. Studies dispute ultraviolet effect on amphibian population declines
8. Studies of spiders silk reveal unusual strength
9. Studies of genes in mice and common worm may accelerate research on blood diseases, cancers
10. Studies offer data on potential impact of Reminyl on caregiver burden in Alzheimers disease
11. Studies: Floyd, other major hurricanes of 99 caused significant changes in nations largest lagoonal estuary

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... 08, 2020 , ... Overcoming Comparability Issues in Regenerative Medicines ... Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/cellandgenetherapy , ... way to complete one? Will the study comply with all FDA requirements? Understanding ...
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... monoclonal antibody development services, today announced that the company has received ISO9001:2015 ... the pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... (PRWEB) , ... June 30, ... ... expert tissue data insights, today announced that the launch of a new ... along with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is ...
(Date:6/28/2020)... , ... June 25, 2020 , ... ... advance photodynamic therapy for treating cancer, today announced the company has entered a ... Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual ...
(Date:6/23/2020)... ... June 23, 2020 , ... DeCurtis Corporation, the premier provider ... Derek Fournier has been appointed CEO and President. Founder and former CEO, David ... , “DeCurtis Corporation has been on an incredible journey for the last twenty ...
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... innovative CNS therapies, today announced that it has filed an Investigational New Drug ... Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with ...
Breaking Biology Technology:
Cached News: